Global Anti-CD20 Monoclonal Antibodies (MABS) Market 2026-2030

Description

The global anti-CD20 monoclonal antibodies (MABS) market is forecasted to grow by USD 15715.6 mn during 2025-2030, accelerating at a CAGR of 11.4% during the forecast period. The report on the global anti-CD20 monoclonal antibodies (MABS) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expanding therapeutic indications beyond oncology into autoimmune disorders, increasing prevalence of hematological malignancies and neuro-inflammatory autoimmune diseases, expansion of biosimilar platforms and patient-centric subcutaneous delivery innovations.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Market Scope
Base Year	2025
End Year	2030
Series Year	2026-2030
Growth Momentum	Accelerate
YOY 2026	10.8%
CAGR	11.4%
Incremental Value	$15715.6 mn

Technavio's global anti-CD20 monoclonal antibodies (MABS) market is segmented as below:

By Product

Oncology
Neurology
Immunology

By Type

First generation
Second generation
Third generation

By End-User

Hospitals and clinics
Academic and research institutions
Contract research organizations

By Drug Class

Rituximab
Ofatumumab
Obinutuzumab
Ublituximab
Others

By Route Of Administration

Intravenous
Subcutaneous

Geography

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
Asia
Rest of World (ROW)
Rest of World (ROW)

This study identifies the emergence and rapid clinical integration of next-generation bispecific anti-cd20 constructs as one of the prime reasons driving the global anti-cd20 monoclonal antibodies (mabs) market growth during the next few years. Also, transition toward high-concentration subcutaneous formulations and outpatient dosing systems and expansion of anti-cd20 monoclonal antibodies into autoimmune, neurological, and renal indications will lead to sizable demand in the market.

The report on the global anti-cd20 monoclonal antibodies (mabs) market covers the following areas:

Global anti-cd20 monoclonal antibodies (mabs) market sizing
Global anti-cd20 monoclonal antibodies (mabs) market forecast
Global anti-cd20 monoclonal antibodies (mabs) market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global anti-cd20 monoclonal antibodies (mabs) market vendors that include AbbVie Inc., Amgen Inc., Biocon Ltd., Biogen Inc., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Genmab AS, Gilead Sciences Inc., Hetero Labs Ltd., Innovent Biologics Inc., Intas Pharmaceuticals Ltd., Mabxience Holding S.L., Novartis AG, Pfizer Inc., Reliance Life Sciences Pvt. Ltd., Sandoz Group AG, Shanghai Henlius Biotech Inc., Teva Pharmaceutical Ltd., TG Therapeutics Inc., Zydus Lifesciences Ltd.. Also, the global anti-cd20 monoclonal antibodies (mabs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR73017

1 Executive Summary

1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Product
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
2.3 Factors of disruption
2.4 Impact of drivers and challenges

3 Market Landscape

3.1 Market ecosystem
3.2 Market characteristics
3.3 Value chain analysis

4 Market Sizing

4.1 Market definition
4.2 Market segment analysis
- Market segments
4.3 Market size 2025
4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

5.1 Global Anti-CD20 Monoclonal Antibodies (MABs) Market 2020 - 2024
- Historic Market Size - Data Table on Global Anti-CD20 Monoclonal Antibodies (MABs) Market 2020 - 2024 ($ million)
5.2 Product segment analysis 2020 - 2024
- Historic Market Size - Product Segment 2020 - 2024 ($ million)
5.3 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
5.4 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
5.5 Drug Class segment analysis 2020 - 2024
- Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
5.6 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
5.7 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
5.8 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

6.1 Impact of AI on Global Anti-CD20 Monoclonal Antibodies (MABs) Market
6.2 Impact of Geopolitical Conflicts on Global Anti-CD20 Monoclonal Antibodies (MABs) Market

7 Five Forces Analysis

7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
7.7 Market condition

8 Market Segmentation by Product

8.1 Market segments
8.2 Comparison by Product
8.3 Oncology - Market size and forecast 2025-2030
8.4 Neurology - Market size and forecast 2025-2030
8.5 Immunology - Market size and forecast 2025-2030
8.6 Market opportunity by Product
- Market opportunity by Product ($ million)

9 Market Segmentation by Type

9.1 Market segments
9.2 Comparison by Type
9.3 First generation - Market size and forecast 2025-2030
9.4 Second generation - Market size and forecast 2025-2030
9.5 Third generation - Market size and forecast 2025-2030
9.6 Market opportunity by Type
- Market opportunity by Type ($ million)

10 Market Segmentation by End-user

10.1 Market segments
10.2 Comparison by End-user
10.3 Hospitals and clinics - Market size and forecast 2025-2030
10.4 Academic and research institutions - Market size and forecast 2025-2030
10.5 Contract research organizations - Market size and forecast 2025-2030
10.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)

11 Market Segmentation by Drug Class

11.1 Market segments
11.2 Comparison by Drug Class
11.3 Rituximab - Market size and forecast 2025-2030
11.4 Ofatumumab - Market size and forecast 2025-2030
11.5 Obinutuzumab - Market size and forecast 2025-2030
11.6 Ublituximab - Market size and forecast 2025-2030
11.7 Others - Market size and forecast 2025-2030
11.8 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ million)

12 Market Segmentation by Route of Administration

12.1 Market segments
12.2 Comparison by Route of Administration
12.3 Intravenous - Market size and forecast 2025-2030
12.4 Subcutaneous - Market size and forecast 2025-2030
12.5 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)

13 Customer Landscape

13.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

14 Geographic Landscape

14.1 Geographic segmentation
14.2 Geographic comparison
14.3 North America - Market size and forecast 2025-2030
- 14.3.1 US - Market size and forecast 2025-2030
- 14.3.2 Canada - Market size and forecast 2025-2030
- 14.3.3 Mexico - Market size and forecast 2025-2030
14.4 Europe - Market size and forecast 2025-2030
- 14.4.1 Germany - Market size and forecast 2025-2030
- 14.4.2 UK - Market size and forecast 2025-2030
- 14.4.3 France - Market size and forecast 2025-2030
- 14.4.4 Italy - Market size and forecast 2025-2030
- 14.4.5 Spain - Market size and forecast 2025-2030
- 14.4.6 The Netherlands - Market size and forecast 2025-2030
14.5 Asia - Market size and forecast 2025-2030
- 14.5.1 China - Market size and forecast 2025-2030
- 14.5.2 Japan - Market size and forecast 2025-2030
- 14.5.3 India - Market size and forecast 2025-2030
- 14.5.4 South Korea - Market size and forecast 2025-2030
- 14.5.5 Indonesia - Market size and forecast 2025-2030
- 14.5.6 Thailand - Market size and forecast 2025-2030
14.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 14.6.1 Brazil - Market size and forecast 2025-2030
- 14.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 14.6.3 UAE - Market size and forecast 2025-2030
- 14.6.4 Turkey - Market size and forecast 2025-2030
- 14.6.5 Argentina - Market size and forecast 2025-2030
- 14.6.6 Colombia - Market size and forecast 2025-2030
- 14.6.7 South Africa - Market size and forecast 2025-2030
- 14.6.8 Israel - Market size and forecast 2025-2030
14.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)

15 Drivers, Challenges, and Opportunity

15.1 Market drivers
- Expanding therapeutic indications beyond oncology into autoimmune disorders
- Increasing prevalence of hematological malignancies and neuro-inflammatory autoimmune diseases
- Expansion of biosimilar platforms and patient-centric subcutaneous delivery innovations
15.2 Market challenges
- Biosimilar price erosion and commercial margin pressure
- Immunological safety risks and heightened regulatory scrutiny
- Complex bioprocessing requirements and cold chain vulnerabilities
15.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
15.4 Market opportunities
- Emergence and rapid clinical integration of next-generation bispecific anti-CD20 constructs
- Transition toward high-concentration subcutaneous formulations and outpatient dosing systems
- Expansion of anti-CD20 monoclonal antibodies into autoimmune, neurological, and renal indications

16 Competitive Landscape

16.1 Overview
16.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
16.3 Landscape disruption
- Overview on factors of disruption
16.4 Industry risks
- Impact of key risks on business

17 Competitive Analysis

17.1 Companies profiled
- Companies covered
17.2 Company ranking index
- Company ranking index
17.3 Market positioning of companies
- Matrix on companies position and classification
17.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
17.5 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
17.6 Biocon Ltd.
- Biocon Ltd. - Overview
- Biocon Ltd. - Business segments
- Biocon Ltd. - Key offerings
- Biocon Ltd. - Segment focus
- SWOT
17.7 Biogen Inc.
- Biogen Inc. - Overview
- Biogen Inc. - Product / Service
- Biogen Inc. - Key news
- Biogen Inc. - Key offerings
- SWOT
17.8 Dr. Reddys Laboratories Ltd.
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key news
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Segment focus
- SWOT
17.9 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
17.10 Gilead Sciences Inc.
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Business segments
- Gilead Sciences Inc. - Key news
- Gilead Sciences Inc. - Key offerings
- Gilead Sciences Inc. - Segment focus
- SWOT
17.11 Hetero Labs Ltd.
- Hetero Labs Ltd. - Overview
- Hetero Labs Ltd. - Product / Service
- Hetero Labs Ltd. - Key offerings
- SWOT
17.12 Innovent Biologics Inc.
- Innovent Biologics Inc. - Overview
- Innovent Biologics Inc. - Product / Service
- Innovent Biologics Inc. - Key news
- Innovent Biologics Inc. - Key offerings
- SWOT
17.13 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
17.14 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
17.15 Sandoz Group AG
- Sandoz Group AG - Overview
- Sandoz Group AG - Business segments
- Sandoz Group AG - Key news
- Sandoz Group AG - Key offerings
- Sandoz Group AG - Segment focus
- SWOT
17.16 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
17.17 TG Therapeutics Inc.
- TG Therapeutics Inc. - Overview
- TG Therapeutics Inc. - Product / Service
- TG Therapeutics Inc. - Key offerings
- SWOT
17.18 Zydus Lifesciences Ltd.
- Zydus Lifesciences Ltd. - Overview
- Zydus Lifesciences Ltd. - Business segments
- Zydus Lifesciences Ltd. - Key news
- Zydus Lifesciences Ltd. - Key offerings
- Zydus Lifesciences Ltd. - Segment focus
- SWOT

18 Appendix

18.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
18.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
18.3 Currency conversion rates for US$
- Currency conversion rates for US$
18.4 Research methodology
- Research methodology
18.5 Data procurement
- Information sources
18.6 Data validation
- Data validation
18.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
18.8 Data synthesis
- Data synthesis
18.9 360 degree market analysis
- 360 degree market analysis
18.10 List of abbreviations
- List of abbreviations